How Do Healthcare Providers Win Against Better-Funded Competitors?
Direct answer: You don't beat a better-funded competitor by matching their spend—you beat them by choosing a position they can't or won't copy. For healthcare providers, that means mapping the two attributes patients and referrers actually decide on (often access and trusted expertise, not price), finding the underserved corner of that map, and concentrating your limited capital there. A Competitive Positioning Map turns "they have more money" into a specific, defensible answer about where you play and where you deliberately don't.
Why "outspend them" is the wrong instinct in healthcare
When a hospital system, private-equity-backed group, or national telehealth brand moves into your market, the reflex is to react on their terms: more marketing, more locations, more service lines. That's a losing game when their balance sheet is bigger than yours.
Healthcare competition is rarely won on raw capacity. Patients and referring physicians choose on a small number of dimensions—perceived clinical quality, access and wait time, continuity of relationship, convenience, and cost/coverage fit. A better-funded competitor can flood the market, but they usually can't be excellent on every dimension at once. National scale often trades against continuity and local trust. Speed-of-access plays often trade against depth of specialty care.
Your job is to find the dimension where their strength is structurally a weakness, and own it.
Building the Competitive Positioning Map
A Competitive Positioning Map plots competitors on a 2x2 defined by the two attributes that most drive patient and referrer choice. Here's a concrete walkthrough for a provider organization.
Step 1 — Identify the decision attributes that actually matter. Don't guess. Pull from three sources:
- Patient reasons for choosing/leaving (intake notes, reviews, NPS verbatims, no-show and switching data).
- Referring-provider feedback—for specialists and imaging groups, referrers are often the real customer.
- Payer and access constraints (in-network status, prior-auth friction, wait times).
Common candidate axes: Access/Convenience (wait time, telehealth, hours, geography) vs. Depth/Trust (subspecialty expertise, continuity, outcomes reputation).
Step 2 — Pick the two axes that best separate the field. Choose axes where competitors actually differ and where patients trade one off against the other. If everyone scores the same on an axis, it's not useful for positioning—drop it.
Step 3 — Plot honestly, including yourself. Place each competitor—the big system, the PE roll-up, urgent-care chains, telehealth entrants, and independents—using evidence, not aspiration. Rate your own organization the way a skeptical referrer would.
Step 4 — Find the white space and the traps. Look for:
- Underserved quadrants where demand exists but no strong competitor sits.
- Crowded quadrants where the well-funded player already dominates—avoid a frontal fight there.
- The trap of the middle: trying to be moderately good on both axes usually means you're beatable on both.
Step 5 — Pressure-test defensibility. For your target position, ask: Can the better-funded competitor copy this quickly? A national brand can buy a clinic; it cannot easily buy 15 years of local physician relationships or same-week access built on a lean operating model. Positions rooted in relationships, local knowledge, operating design, and focus are the hardest to outspend.
What "good" looks like: one clearly chosen quadrant, an explicit list of things you will not do, and a resource plan that concentrates capital on the two or three capabilities that make that position real (e.g., referral-network management, access engineering, a narrow high-margin service line).
Turning the map into an execution plan
A map is a diagnosis. The win comes from reallocating scarce resources toward the chosen position and away from unwinnable fights. That means:
- Service-line pruning: exit or de-emphasize lines where the funded competitor dominates and you sub-scale.
- Access investment: if you're claiming the access quadrant, fund scheduling, telehealth, and staffing before marketing.
- Referral strategy: name the referrers who matter and build the relationship program deliberately.
- A financial view: model the margin and volume impact of concentrating vs. spreading, so the board sees the trade-off in dollars, not adjectives.
Where Percision fits—and where it doesn't
Disclosure: I work on content for Percision (percision.app), a strategic intelligence platform, so treat this as one option among several.
Percision can run your business context through a structured reasoning process—including a Competitive Positioning Map among its 27+ frameworks—to produce a board-ready draft in minutes rather than weeks: candidate axes, a plotted competitive landscape, white-space hypotheses, and a first-cut resource-reallocation plan with supporting financial analysis (DCF, ratios, warning signs) and an exportable model. It's positioned as a co-pilot, not an autopilot—your leadership team validates the axes and the clinical realities, because the tool doesn't know your referrers or your market the way you do.
Independent research points to genuine gains from AI on analytical knowledge work—for example, a 2023 field experiment by Harvard Business School and BCG (the "jagged frontier" study) found consultants using GPT-4 completed tasks faster and at higher quality within the tool's competence. That's a reason to use AI for the heavy synthesis, not to hand it the judgment.
When you don't need Percision:
- If the choice is already obvious and the team agrees, a whiteboard and a spreadsheet are enough.
- If your problem is a delicate physician-partnership or governance negotiation, a human advisor who knows the local politics matters more than any model.
- If your data is too thin to plot competitors honestly, spend your effort collecting patient and referrer input first.
Use the platform to accelerate the analysis and free your leaders to argue about the decision. Explore it at percision.app.
What this looks like when the analysis is actually run
An independent group cannot outspend a hospital system. It can own a capability the system's scale actively makes harder.
The subject is Cedar Ridge Health Partners, a sample company profile we use for testing rather than a customer: a physician-owned multi-specialty group, $196M net patient revenue, 128 physicians, 14 clinics.
Excerpt from a real Percision run · Customer Value Architecture (T14) · sample company profile
The capability, and the compounding behind it. The loop runs from 212,000 attributed lives to a cost-measurement platform, to validated savings, to licensing revenue, to 128 physicians adopting, to more lives. Each additional attributed life improves actuarial precision and raises the licensing price by 3–5%.
What it becomes. Once cost measurement is validated on the internal 38,000-life panel, the same data schema and compliance playbooks are licensed as a SaaS module to the remaining 128 physician-owners and subsequently to independent practices in the two metros. Year 2: $4.2M licensing ARR — 40 physicians × $120K plus 5 external practices × $400K. Year 3: $13.5M — 90 physicians × $120K plus 18 external practices × $400K.
The asset a system cannot copy locally. The ASC provides the surgical capacity competitors cannot replicate inside the same catchment, and the 212,000 attributed lives provide the population base for credible pricing.
What it is worth. 6.3–16.7× cash-on-cash within 36 months on $2.1–3.5M, against a $196M revenue base.
| Metric | Target | By |
|---|---|---|
| Platform variance vs manual abstraction | ≤5 % by Month 18 | Month 18 |
| Physician licensing adoption rate | 70 % of 128 physicians by Month 24 | Month 24 |
| External practice licensing ARR | $7.2 M by Month 36 | Month 36 |
The winning move is to sell to the competition's suppliers. Independent practices in the same two metros face the identical measurement problem and have no way to solve it alone — so the group's own solution becomes a $400K-a-year product for eighteen of them, funded by a build it needed anyway.
The 3–5% price escalation per additional attributed life is the part a better-funded rival cannot simply outspend. Actuarial precision improves with panel size, and the panel grows as practices license the platform. Money buys a platform; it does not buy the lives that make the platform accurate.
Read a complete Percision report — every page, no email required.
FAQ
What two axes should a provider use for the map? Start with the attributes your patients and referrers actually decide on—commonly Access/Convenience and Depth/Trust. Validate with intake data and referrer feedback before committing; the right axes are market-specific.
How do we defend a position from a competitor who can just buy it? Choose positions rooted in things capital can't quickly replicate: local referral relationships, continuity of care, operating design that delivers speed, and narrow focus. Copying money is easy; copying trust and lean execution is slow.
Can we win without exiting any service lines? Rarely against a better-funded rival. Concentration is the whole point—spreading limited capital to defend everything usually means losing where it matters most.